AstraZeneca's Blockbuster Cancer Drug Imfinzi Flunks As Follow-Up In Type Of Early-Stage Lung Cancer, But Hits Primary Goal In Phase 3 Bladder Cancer Study

AstraZeneca's Imfinzi failed to meet the primary endpoint in the ADJUVANT BR.31 trial for early-stage lung cancer. However, it showed positive results in bladder cancer and small-cell lung cancer trials, positioning it as a potential treatment option in these areas.